Best Life Sciences Companies in Bethesda, United States
The 35 best Life Sciences companies in Bethesda, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: adaptive phage therapeutics.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Bethesda
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | adaptive phage therapeutics Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic… | $108M | 39 mo ago | 66 | — | — | — | — |
| 2 | ValenzaBio Developer of treatments for autoimmune and inflammatory diseases | $79M | 65 mo ago | 17 | — | — | — | — |
| 3 | Telcare Cellular technology and social networking to tackle diabetes | $67M | 143 mo ago | 26 | — | — | 16 patents Portable blood glucose meters with integrated messaging for real-time health data transmission. | — |
| 4 | BrainScope Provider of AI-powered non-invasive medical devices for diagnosing and assessing brain injuries, including… | $62M | 36 mo ago | 38 38 → 34 (-11%) | Michael Singer Co-CEO | HubSpot CMS HubEnvoyBootstrap+15 | 165 patents Portable EEG/neurological assessment devices for concussion diagnosis and brain function monitoring | — |
| 5 | Mana Therapeutics Developer of therapies for the treatment of cancer | $35M | 57 mo ago | 9 | Catherine Bollard Co-Founder | — | — | — |
| 6 | RightEye Provider of eye-tracking solution for general healthcare and wellness | $11M | 78 mo ago | 14 | — | WordPress Block EditorWordPressMySQL+33 | 34 patents Eye‑tracking based physiological and visual performance assessment and calibration technologies. | — |
| 7 | Pocket Naloxone Developer of FDA approved devices for opioid overdoses management | $6M | 66 mo ago | 13 | Ashanthi Mathai Co-Founder & CEO | MagentoKlevuMySQL+15 | 22 patents Portable drug delivery devices for rapid naloxone administration in opioid overdose | — |
| 8 | DioGenix Next generation sequencing tests for multiple sclerosis. | $5M | 153 mo ago | — | — | Microsoft ASP.NETcore-jsSlick+11 | — | — |
| 9 | InforMax Scientific solutions provider: instruments, reagents, software, and services for researchers | $4M | 326 mo ago | 223 | Alex Titomirov Founder | — | — | — |
| 10 | Immune Therapeutics Specialty pharma developing immunotherapies such as Low Dose Naltrexone (LDN) | $4M | 49 mo ago | 4 | — | — | — | — |
| 11 | Auscultech Dx Developer of computer-aided auscultation for pediatric applications | $2M | 16 mo ago | — | Robin Doroshow Co-Founder and Chief Medical Officer | — | 3 patents AI-powered throat imaging diagnostics and digital stethoscope signal analysis for respiratory health | — |
| 12 | Northwest Biotherapeutics Developer of dendritic cell-based vaccines for prostate and brain cancer | $2M | 21 mo ago | 22 | — | WordPressMySQLPHP+18 | 250 patents Dendritic cell cancer vaccines and combination checkpoint‑inhibitor immunotherapies | — |
| 13 | Solaxa Developer of therapeutics for rare neurodegenerative disease and acute nerve injuries | $2M | 25 mo ago | — | Christian Walker Founder & CEO | WordPressMySQLPHP+7 | — | — |
| 14 | RespondHealth Provider of an AI-based platform focused on clinical discovery to real-world health emergencies | $2M | 149 mo ago | — | Vicki Seyfert-Margolis Founder & CEO | — | — | 1 launch |
| 15 | BioDatomics Next-generation bioinformatics tools for accelerated NGS data analysis and collaboration | $1M | 130 mo ago | 11 | Alan Taffel Co-Founder & CEO | — | 11 patents Patents concentrated in computing, sensing & instrumentation | — |
| 16 | Awarables Wearable and mobile app for sleep disorder identification & management via coaching and behavior modification | $500K | 120 mo ago | 3 | Madhvi Upender Co-Founder & CEO | — | 6 patents Sleep monitoring and analysis using wearable sensor data | — |
| 17 | Immage Biotherapeutics DNA viral vaccine construct targeted to tumors that expresses the Melanoma antigen family – A (MAGE-A)… | $500K | 126 mo ago | 4 | — | — | — | — |
| 18 | ImmunoBlue Developer of nanoimmunotherapies for cancer treatment using nanotechnology and immunotherapy | $400K | 24 mo ago | — | Rohan Fernandes Founder and CEO | — | — | — |
| 19 | Audiodontics Non-invasive, wireless, bone-conduction based hearing aid | $350K | 132 mo ago | — | Barry Mersky Founder & CEO | — | 6 patents Bone-conduction hearing measurement and intra‑oral low‑power wireless antenna alignment | — |
| 20 | Digidence Online platform for patient enegagement and data management | $150K | 93 mo ago | 3 | — | — | — | — |
Top 12 Life Sciences companies in Bethesda
#1
Funding Raised · Bethesda, Maryland · founded 2013$2.4Mraised▾
Developer of computer-aided auscultation for pediatric applications. The flagship product StethAid is a digital stethoscope that is compatible with mobile phones. It uses a proprietary algorithm to distinguish between pathological murmurs and Still's murmurs in pediatric patients at the point of care.
- Apr 2025Grant (prize money)$256.3K
- Jan 2023Grant (prize money)$256.3K
- Aug 2020Grant (prize money)$257.9K
- Sep 2016Grant (prize money)$1.7M
#2
Public · Bethesda, Maryland · founded 1998 · 22 employees$2.4Mraised▾
Northwest Biotherapeutics is a developer of dendritic cell-based vaccines for prostate and brain cancer. It focused on discovering & developing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company’s platform technology, DCVax, uses a patient’s own dendritic cells, the starter engine of the immune system. The dendritic cells are extracted from the body, loaded with tumor biomarkers or antigens. Injection of these cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. The Company’s lead product candidate is DCVax-Brain which targets Glioblastoma Multiforme. Other developmental programs include DCVax-Prostate, which targets hormone-independent prostate cancer.
- Dec 2024Post IPO$5M
- Dec 2021Post IPO$15M
- Aug 2020Post IPO—
- Nov 2018Conventional Debt$5M
#3
Series B · Bethesda, Maryland · founded 2006 · 38 employees$62.2Mraised▾
Provider of AI-powered non-invasive medical devices for diagnosing and assessing brain injuries, including concussions and brain bleeds.
- Sep 2023Series B—
- Oct 2021Series B—
- Aug 2017Series B$16.4M
- Sep 2015Series B$2.5M
#4
Acquired · Bethesda, Maryland · founded 2016 · 66 employees$107.9Mraised▾
Operator of a clinical-stage company intended to treat multi-drug resistant pathogenic bacteria. The company provides services by using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistant bacteria.
#5
Seed · Bethesda, Maryland · founded 2021$2.1Mraised▾
Developer of therapeutics for rare neurodegenerative disease and acute nerve injuries. The company focused on developing novel and reformulated drugs to restore nerve function by targeting ion channels. The company's product line include SLX-001 showing immense promise in treating cerebellar ataxias.
- Jul 2024Seed$500K
- Apr 2024Seed$365K
- Nov 2023Seed$500K
- Feb 2021Seed$729K
#6
Acqui-Hired · Bethesda, Maryland · founded 2019 · 17 employees$79.4Mraised▾
Developer of treatments for autoimmune and inflammatory diseases. The lead product VB119 is an IgG1 monoclonal antibody that binds with CD-19, a B-cell surface receptor, and treats membranous nephropathy. The other product is VB421 that binds IGF-1R with sub-50 pM and is used for the treatment of thyroid eye disease.
- Apr 2021Series A$79.4M
#7
Deadpooled · Bethesda, Maryland · founded 2017 · 9 employees$35Mraised▾
Developer of therapies for the treatment of cancer. The company uses EDIFY platform to develop cell therapies for cancer patients. The product pipeline includes MANA-312 an allogeneic donor-derived cell therapy for the treatment of acute myeloid leukemia, MANA-412 for solid tumors, and MANA-512 for multiple cancers.
- Nov 2021Venture Debt$7.5M
- Nov 2021Series A—
- Jan 2021Series A$35M
#8
Funding Raised · Bethesda, Maryland · founded 2016$399.7Kraised▾
Developer of nanoimmunotherapies for cancer treatment using nanotechnology and immunotherapy. It engineers novel therapies by combining these principles to treat cancer.
- Sep 2024Grant (prize money)$399.7K
#9
Acquired · Bethesda, Maryland · founded 2008 · 26 employees$66.7Mraised▾
Cellular technology and social networking to tackle diabetes. It provides a wireless blood glucose meter with two-way messaging, that transmits to a care management server, along with a suite of iPhone and Android apps. It sends reminders and messages, with personalized education to patients.
- Oct 2014Series C$34.7M
- Aug 2012Series B$25.4M
- Feb 2012Series A$2.1M
- May 2011Conventional Debt$1M
#10
Public · Bethesda, Maryland · founded 1993 · 4 employees$3.7Mraised▾
Immune Therapeutics develops products, technologies, and patents that are designed to harness the power of the immune system to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. They are currently developing active and adoptive forms of immunotherapies. Their most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone, which both work by triggering opioid receptors on immune cells and lead to activation and expansion of various cells in the immune system.
- Aug 2022Post IPO$400K
- Mar 2015Post IPO$200K
- Sep 2013Post IPO$2.9M
- Sep 2012Post IPO$200K
#11
Series A · Bethesda, Maryland · founded 2012 · 14 employees$11.3Mraised▾
RightEye develops eye-tracking technology for applications in the healthcare industry. The company’s patented solutions measure the user's visual skills and provide insights into the user's health. Its solutions are Functional Vision EyeQ (for eye test); Brain Health EyeQ (brain health test based on eye-tracking); Reading EyeQ (eye-tracking system for children); Sports Vision EyeQ (eye test for athletes) and, EyeQ Trainer (application based eye exercises for patients). The software processes the collected data in real time and creates an individualized profile of vision performance and health. The vision and health recommendations provided to the user on the basis of the generated profile.
- Mar 2020Conventional Debt$1M
- Oct 2018Series A$1.5M
- Sep 2017Series A—
- Jun 2017Series A$7.3M
#12
Series A · Bethesda, Maryland · founded 2019 · 13 employees$6.2Mraised▾
Developer of FDA approved devices for opioid overdoses management. The platform offers Naloxone Hydrochloride product that acts as an antidote to reverses opioid overdoses and prevents avoidable deaths.
- Mar 2021Series A$6.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Who's building biotechnology IP in Bethesda
- generali global assistance north america4bethesda
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.